Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.55 |
| ▸ | MMP3 | P08254 | 12/20 | 0.55 |
| ▸ | MMP1 | P03956 | 10/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | MMP7 | P09237 | 6/20 | 0.52 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017227 | 0.98 | MMP2 (0.57) | MMP2MMP3MMP1FOLH1CSNK1E | |
| SCHEMBL28211408 | 0.98 | MMP2 (0.57) | MMP2MMP3MMP1FOLH1CSNK1E | |
| SCHEMBL2948787 | 0.95 | FOLH1 (0.54) | MMP2MMP3MMP1FOLH1 | |
| SCHEMBL8728655 | 0.95 | FOLH1 (0.54) | MMP2MMP3MMP1FOLH1 | |
| SCHEMBL10778624 | 0.88 | FOLH1 (0.68) | MMP2MMP3MMP1FOLH1CSNK1E | |
| SCHEMBL14520756 | 0.88 | HDAC3 (0.59) | FOLH1 | |
| SCHEMBL10955140 | 0.87 | FOLH1 (0.66) | MMP2MMP3MMP1FOLH1CSNK1E | |
| SCHEMBL3242850 | 0.87 | FOLH1 (0.66) | MMP2MMP3MMP1FOLH1CSNK1E | |
| SCHEMBL9655121 | 0.87 | FOLH1 (0.66) | MMP2MMP3MMP1FOLH1CSNK1E | |
| SCHEMBL9653477 | 0.87 | FOLH1 (0.66) | MMP2MMP3MMP1FOLH1CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | claimed |
| EP-2152658-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2010-02-17 | — | — | EP | claimed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | claimed |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2152658-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | Givaudan SA (CH) | 2010-02-17 | — | — | EP | disclosed |
| EP-2139354-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116338-A2 | ORGANIC COMPOUNDS AND COMPOSITIONS HAVING THE ABILITY TO MODULATE FRAGRANCE COMPOSITIONS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | MMP2 414/4885MMP3 551/4885MMP1 1898/4885 |
| US-20100111888-A1 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions | CYP2A13, CYP1A1, CYP1B1 | MMP2 1658/4885MMP3 932/4885MMP1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.